Novartis operates in more than 30 production sites worldwide. Our sites are fully focused on producing innovative medicines across our priority technology platforms. Overall, we manufactured over 20 billion treatments for patients in 2024, ensuring a continuous and reliable supply of our medicines to patients.
Kate Kostelyk, IgA nephropathy (IgAN) patient, and her labrador Dakoda in Mims, Florida

Transforming manufacturing

The Novartis in Society Integrated Report 2024 describes how our manufacturing operations are evolving as we embrace operational excellence.


Our leadership

Steffen Lang, Ph.D., President, Operations
Steffen Lang, Ph.D.
President, Operations

Quality

Quality is a key priority in every aspect of our work. Our patients are relying on us to deliver the highest quality standards, and we are committed to living up to their expectations.

Learn more